Cancer image analysis software to be tested:
This article was originally published in Clinica
Executive Summary
Confirma is to begin two clinical studies to assess its ACCENT data analysis software product that works with MRI to determine the extent of disease in cancer patients. The product, which is designed to provide information about both the location and volume of cancerous tumours, will be tested in patients with either breast or prostate cancer. The ACCENT system provides information that is critical to treatment planning and for following the progress of therapy, said the Kirkland, Washington-based company.